Comparison of Peripheral Neurotoxicity of Weekly Paclitaxel Versus Thrice Weekly Paclitaxel Chemotherapy Among Cancer Patients
DOI:
https://doi.org/10.51253/pafmj.v74i5.7737Keywords:
Cancer, Neurotoxicity, Oncology, Paclitaxel.Abstract
Objective: To compare peripheral neurotoxicity of weekly Paclitaxel vs thrice weekly Paclitaxel chemotherapy among cancer patients.
Study Design: Quasi-experimental study.
Place and Duration of study: Oncology Department, Combined Military Hospital, Rawalpindi, Pakistan from Feb to Nov 2021.
Methodology: We enrolled 200 patients with diagnosed malignancies taking Paclitaxel chemotherapy for more than three months and less than one year. They were divided into two groups: Group-A received Paclitaxel weekly while Group-B received this medication thrice weekly. Peripheral neurotoxicity was assessed by consultant oncologist on the basis of Eastern Cooperative Oncology Group score and patients in both groups were categorised into four grades from 0 to 3, on the basis of clinical symptoms described in ECOG score.
Results: Out of 200 cancer patients prescribed Paclitaxel, 67(33.5%) were male while 133(66.5%) were female, 107(53.5%) received Paclitaxel weekly while 93(46.5%) received thrice weekly, 65(32.5%) had Grade 0 neuropathy, 90(45%) had Grade-I, 42(21%) had Grade-II while 03(1.5%) had Grade-III neuropathy. Dosage schedule was not associated with presence and severity of neurotoxicity.
Conclusion: A significant number of cancer patients using Paclitaxel had presence of neuropathy in our study, regardless of weekly or thrice weekly dosing of Paclitaxel.
Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1): 7-30. https://doi.org/10.3322/caac.21590
Abbas G, Shah S, Hanif M, Asghar A, Shafique M, Ashraf K. Cancer prevalence, incidence and mortality rates in Pakistan in 2018. Bull Cancer 2020; 107(4): 517-518.
https://doi.org/10.1016/j.bulcan.2019.12.011
Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience 2019; 13: 961.
https://doi.org/10.3332/ecancer.2019.961
Altun İ, Sonkaya A. The most common side effects experienced by patients were receiving first cycle of chemotherapy. Iran J Public Health 2018; 47(8): 1218-1219.
Gordon-Williams R, Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000Res. 2020; 9: F1000 Faculty Rev-177.
https://doi.org/10.12688/f1000research.21625.1
Tan AC, McCrary JM, Park SB, Trinh T, Goldstein D. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE Grade. Support Care Cancer 2019; 27(12): 4771-4777.
https://doi.org/10.1007/s00520-019-04781-6
Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, et al. Weekly Paclitaxel -induced neurotoxicity in breast cancer: outcomes and dose response. Oncologist 2021; 26(5): 366-374.
https://doi.org/10.1002/onco.13697
Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks Paclitaxel in the treatment of advanced solid tumors: a meta-analysis. 2012. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews York (UK): Centre for Reviews and Dissemination (UK). [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK114933/
Kawashiri T, Inoue M, Mori K, Kobayashi D, Mine K, Ushio S, et al. Preclinical and clinical evidence of therapeutic agents for Paclitaxel -induced peripheral neuropathy. Int J Mol Sci 2021; 22(16): 8733. https://doi.org/10.3390/ijms22168733
Ullah R, Ali G, Subhan F, Naveed M, Khan A, Khan J, et al. Attenuation of nociceptive and Paclitaxel -induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone. Neurochem Int 2021; 144: 104981.
https://doi.org/10.1016/j.neuint.2021.104981
Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, et al. Hemoglobin, body mass index, and age as risk factors for Paclitaxel - and oxaliplatin-induced peripheral neuropathy. JAMA Netw Open 2021; 4(2): e2036695.
https://doi.org/10.1001/jamanetworkopen.2020.36695
Farrar MC, Jacobs TF. Paclitaxel . [Updated 2021 Jul 19]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
Azam F, Latif MF, Farooq A. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol 2019; 12(3): 728-736.
https://doi.org/10.1159/000503095
Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?. Front Pharmacol 2018; 9: 245.
https://doi.org/10.3389/fphar.2018.00245
Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, et al. Risk factors for Paclitaxel -induced peripheral neuropathy in patients with breast cancer. BMC Cancer 2018; 18(1): 958. https://doi.org/10.1186/s12885-018-4869-5
Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev. 2010; 36(1): 69-74.
https://doi.org/10.1016/j.ctrv.2009.10.006
Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J, et al. A meta-analysis of Paclitaxel -based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 2012; 76(3): 380-386.
https://doi.org/10.1016/j.lungcan.2011.12.001
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, et al. Weekly vs. every-3-week Paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016; 374(8): 738-748.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Tahir Manzoor Lone, Zulfiqar Ali Amin, Zeeshan Ahmed Alvi, Muhammad Nadeem, Misbah Hamid, Amjad Khan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
